AstraZeneca Partners Vanguard Renewables To Use Renewable Natural Gas In The U.S. By End Of 2026

RTTNews | 1186 days ago

(RTTNews) - In a first-of-its-kind collaboration, British drug major AstraZeneca plc (AZN, AZN.L) is partnering with Vanguard Renewables to enable the delivery of renewable natural gas (RNG) to all of its sites in the United States by the end of 2026.

From June 2023, AstraZeneca will begin purchasing RNG produced by Vanguard Renewables for its Newark Campus in Delaware, where the Company packages 26 medicines for distribution across the U.S. and makes medicine formulations for global supply.

By 2026, this collaboration will enable as much as 650,000 million British thermal units (MMBtu), or 190,500 megawatt hours (MWh) per year, of RNG to be used across AstraZeneca's U.S. sites, equivalent to the energy required to heat more than 17,800 U.S. homes for a year.

This new partnership with Vanguard Renewables is an important milestone in delivering emissions reductions in line with AstraZeneca's flagship Ambition Zero Carbon program.

The Company is on track to reduce greenhouse gas (GHG) emissions from its global operations (Scope 1 and 2) by 98% by 2026 from a 2015 baseline, and by 2030, AstraZeneca aims to halve its entire value chain footprint on the way to becoming science-based net zero by 2045 at the latest.

The use of RNG at AstraZeneca sites in the U.S. will further enable the company's transition to 100 percent renewable energy for heat and power.

Through the partnership with Vanguard Renewables, AstraZeneca will access high quality RNG from three on-farm anaerobic digester facilities across the U.S. for the next 15 years or more.

Tags: AZN AZN.L

AstraZeneca Q2 Pre-tax Profit Down, But EPS Rise; Backs Positive FY26 View

British drug major AstraZeneca PLC reported Monday lower pre-tax pofit in its second quarter mainly on lower tax expenses, while earnings per share grew from last year with higher revenues, excluding weak China results. Further, the firm confirmed fiscal 2026 outlook for core earnings and revenue growth.

RTTNews | 46 days ago

Amgen's Bkemv Approved As First Interchangeable Biosimilar To Soliris

The U.S. Food and Drug Administration has approved Amgen Inc.'s Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab), developed by British drug major AstraZeneca's Rare Disease unit Alexion Pharmaceuticals, to treat certain rare diseases. Soliris is a medicine used to treat adults and children with paroxysmal nocturnal haemoglobinuria or PNH...

RTTNews | 834 days ago

Amazon, Microsoft, Pfizer To Invest Billions In French Projects

Major companies, including Amazon.com Inc., Microsoft Corp., Morgan Stanley, Pfizer and others, have announced around 15 billion euros or $16.2 billion worth foreign investments in France as part of the country's annual 'Choose France' business summit, reports said. French President Emmanuel Macron kicks off the summit of 180 CEOs and executives on Monday, aiming to showcase foreign investment.

RTTNews | 851 days ago

AstraZeneca To Withdraw Its Covid-19 Vaccine Vaxzevria Worldwide

AstraZeneca, a major provider of Covid-19 vaccines across the world mainly during the initial pandemic period, has initiated a process to withdraw its Vaxzevria COVID-19 vaccine worldwide, citing weak demand and the surplus availability of new vaccines. Meanwhile, AstraZeneca reportedly had admitted recently in court documents that the vaccine could cause side-effects such as blood clots...

RTTNews | 856 days ago

AstraZeneca Says AIRSUPRA Now Commercially Available In US As FDA-approved Option For Asthma

AstraZeneca (AZN, AZN.L) announces Monday that AIRSUPRA (albuterol/budesonide) is now commercially available in the US by prescription. AIRSUPRA was approved based on the results from two Phase III trials, MANDALA and DENALI.

RTTNews | 963 days ago

Compugen To Receive $10 Mln Payment After Dosing First Patient In AstraZeneca's ARTEMIDE-Bil01 Trial

Cancer immunotherapy company Compugen Ltd. (CGEN) announced Monday that Compugen is entitled to receive a $10 million milestone payment from British drug major AstraZeneca (AZN), after the first patient was dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig.

RTTNews | 977 days ago

Allorion Therapeutic Inks Agreement With AstraZeneca For EGFR L858R Allosteric Inhibitor Program

Allorion Therapeutics, a US and China-based biotechnology company, on Tuesday entered into an exclusive option and global license agreement with British drug major AstraZeneca plc (AZN) to develop and commercialize a novel epidermal growth factor receptor (EGFR) L858R mutated allosteric inhibitor, as a potential new treatment for advanced EGFR-mutant non-small cell lung cancer (NSCLC).

RTTNews | 983 days ago

AstraZeneca Files Legal Challenge To Protect Access To Medicines For Cancer And Rare Diseases

AstraZeneca plc (AZN) said Friday it has filed a legal challenge to critical aspects of the drug price negotiation provisions of the Inflation Reduction Act (IRA) to help protect access to medicines for cancer and rare disease patients.

RTTNews | 1113 days ago

EURUSD	1.16005	GBPUSD	1.3518
USDJPY	153.579	USDCAD	1.38632